Grenader Tal, Shavit Linda
Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
Division of Adult Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel.
Korean J Urol. 2015 Dec;56(12):791-5. doi: 10.4111/kju.2015.56.12.791. Epub 2015 Dec 10.
Although angiogenesis has been implicated in the promotion of renal cyst growth in autosomal dominant polycystic kidney disease, no studies have investigated the role of angiogenesis in the growth of simple renal cysts. The aim of current study was to investigate the effect of chemotherapy with the antivascular endothelial growth factor antibody bevacizumab on renal cyst development and growth in cancer patients.
We retrospectively reviewed the medical records of 136 patients with a variety of cancers that were treated with bevacizumab-based chemotherapy for metastatic disease. The presence of and changes in renal cysts were evaluated by retrospective analysis of computed tomography scans performed for assessment of tumor response to bevacizumab-based therapy.
The median age of the patients was 64 years. Renal cysts were identified in 66 patients, in whom 33 (50%) had a single cyst and the rest had 2 or more cysts. The average dose of bevacizumab was 2.68 mg/kg per week. Median duration of treatment was 33 weeks. Average cyst size was 1.9±2.4 cm at the beginning of the study and the majority of the cysts (54 patients, 84%) did not change in size or shape during bevacizumab treatment. No patients were identified with new cysts. Cyst size changed in 10 patients (16%): an increase of 15% to 40% from the baseline size in 5 patients and a decrease in size of 10% to 70% in another 5 patients. The duration of bevacizumab therapy was significantly longer in the subgroup of patients with diminished or increased cyst size than in the patients with stable cyst size: 62 weeks versus 29 weeks, respectively (p=0.0002).
Our data demonstrated that simple renal cysts were stable in size and number in the vast majority of cancer patients treated with bevacizumab.
虽然血管生成被认为与常染色体显性多囊肾病中肾囊肿的生长有关，但尚无研究探讨血管生成在单纯性肾囊肿生长中的作用。本研究的目的是调查使用抗血管内皮生长因子抗体贝伐单抗进行化疗对癌症患者肾囊肿发生和生长的影响。
我们回顾性分析了136例因转移性疾病接受基于贝伐单抗化疗的各类癌症患者的病历。通过对为评估基于贝伐单抗治疗的肿瘤反应而进行的计算机断层扫描进行回顾性分析，评估肾囊肿的存在和变化。
患者的中位年龄为64岁。66例患者发现有肾囊肿，其中33例（50%）有单个囊肿，其余患者有2个或更多囊肿。贝伐单抗的平均剂量为每周2.68mg/kg。中位治疗持续时间为33周。研究开始时囊肿平均大小为1.9±2.4cm，在贝伐单抗治疗期间，大多数囊肿（54例，84%）大小和形状未改变。未发现有新囊肿的患者。10例患者（16%）的囊肿大小发生了变化：5例患者囊肿大小较基线增大15%至40%，另外5例患者囊肿大小减小10%至70%。囊肿大小减小或增大的患者亚组中，贝伐单抗治疗持续时间显著长于囊肿大小稳定的患者亚组：分别为62周和29周（p=0.0002）。
我们的数据表明，在大多数接受贝伐单抗治疗的癌症患者中，单纯性肾囊肿的大小和数量是稳定的。
